N-[(3-氨基-1H-吲唑-6-基)甲基]氨基甲酸叔丁酯 | 368426-74-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: N-[(3-氨基-1H-吲唑-6-基)甲基]氨基甲酸叔丁酯
• 英文名称: tert-butyl N-[(3-amino-1H-indazol-6-yl)methyl]carbamate
• CAS: 368426-74-8
• 化学式: C₁₃H₁₈N₄O₂
• 分子量: 262.312
• InChiKey: VVTGZXVFPFQQBQ-UHFFFAOYSA-N

物化性质

• 沸点：
  514.1±40.0 °C(Predicted)
• 密度：
  1.257±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  93
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-[(3-氨基-1H-吲唑-6-基)甲基]氨基甲酸叔丁酯 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 生成 6-(aminomethyl)-1H-indazol-3-amine;hydrochloride
  参考文献：
  名称：

  Non-covalent thrombin inhibitors featuring P3-Heterocycles with P1-Bicyclic arginine surrogates

  摘要：

  Novel, potent, and highly selective classes of thrombin inhibitors were identified, which resulted from judicious combination of P-4-aromatics and P-2-P-3-heterocyclic dipeptide surrogates with weakly basic (calcd pK(a) similar tonon-basic-8.6) bicyclic P-1-arginine mimics. The design, synthesis, and biological activity of achiral, non-covalent, orally bioavailable inhibitors NC1-NC44 featuring P-1-indazoles, benzimidazoles, indoles, benzotriazoles, and aminobenzisoxazoles is disclosed. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00585-1
• 作为产物：
  描述：

  2-氟-4-甲基苯腈 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 、 caesium carbonate 、 肼 作用下， 以 四氯化碳 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 正丁醇 为溶剂， 反应 28.08h， 生成 N-[(3-氨基-1H-吲唑-6-基)甲基]氨基甲酸叔丁酯
  参考文献：
  名称：

  Non-covalent thrombin inhibitors featuring P3-Heterocycles with P1-Bicyclic arginine surrogates

  摘要：

  Novel, potent, and highly selective classes of thrombin inhibitors were identified, which resulted from judicious combination of P-4-aromatics and P-2-P-3-heterocyclic dipeptide surrogates with weakly basic (calcd pK(a) similar tonon-basic-8.6) bicyclic P-1-arginine mimics. The design, synthesis, and biological activity of achiral, non-covalent, orally bioavailable inhibitors NC1-NC44 featuring P-1-indazoles, benzimidazoles, indoles, benzotriazoles, and aminobenzisoxazoles is disclosed. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00585-1

文献信息

• TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3122344B1

  公开（公告）日：2022-04-27
• Non-covalent thrombin inhibitors featuring P3-Heterocycles with P1-Bicyclic arginine surrogates
  作者：Jingrong Jean Cui、Gian-Luca Araldi、John E Reiner、Komandla Malla Reddy、Scott J Kemp、Jonathan Z Ho、Daniel V Siev、Lala Mamedova、Tony S Gibson、John A Gaudette、Nathaniel K Minami、Susanne M Anderson、Annette E Bradbury、Thomas G Nolan、J.Edward Semple

  DOI：10.1016/s0960-894x(02)00585-1

  日期：2002.10

  Novel, potent, and highly selective classes of thrombin inhibitors were identified, which resulted from judicious combination of P-4-aromatics and P-2-P-3-heterocyclic dipeptide surrogates with weakly basic (calcd pK(a) similar tonon-basic-8.6) bicyclic P-1-arginine mimics. The design, synthesis, and biological activity of achiral, non-covalent, orally bioavailable inhibitors NC1-NC44 featuring P-1-indazoles, benzimidazoles, indoles, benzotriazoles, and aminobenzisoxazoles is disclosed. (C) 2002 Elsevier Science Ltd. All rights reserved.